Pharmaceutical MNCs Invest In China’s Diabetes Sector
This article was originally published in PharmAsia News
Executive Summary
The Chinese Diabetes Society recently released its latest survey results prior to World Diabetes Day Nov. 14. According to statistics, the diabetes population in China now stands at 39.8 million, second only to India's 40.9 million. Diabetes morbidity rates from age 20 to 70 years have doubled and quadrupled those of 2001 and 1994, respectively; the number of diabetics in China is expected to hit 59.3 million by 2025. Eyeing the huge market, Novo Nordisk will be building the world's largest insulin factory in Tianjin (PharmAsia News, Nov. 10, 2008). Other MNCs such as Lilly, Sanofi-Aventis and Bayer have plans to expand their investment in China's diabetes sector by enlarging operations, constructing plants or introducing new drugs. (Click here for more - Chinese Language)